Comparing Effectiveness and Safety of Left Atrial Appendage Closure Devices: A Network Meta‐Analysis of Randomized Controlled Trials
Clinical Cardiology · 2025
DOI: 10.1002/clc.70217 ↗Kurz gefasst
Netzwerk-Metaanalyse in der Zeitschrift Clinical Cardiology, 2025. Verfasst von John W Davis und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Washington University in St. Louis/Barnes-Jewish Hospital, St. Louis, Missouri, USA. Hauptthemen laut MEDLINE: Atrial Appendage, Atrial Fibrillation, Left Atrial Appendage Closure, Septal Occluder Device. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Atrial fibrillation‐related stroke is a leading cause of morbidity and mortality. The comparative effectiveness and safety of left atrial appendage closure (LAAC) devices, compared with one another and with anticoagulation, is unclear.
Methods
We conducted a systematic review and network meta‐analysis (NMA) of all clinical trials comparing the Watchman and Amplatzer Amulet LAAC devices with each other or with warfarin or direct oral anticoagulants (DOACs). The primary comparison was between LAAC devices with secondary comparisons to anticoagulation. The primary effectiveness outcomes were any stroke and all‐cause death. Safety outcomes included any thromboembolism, device embolization, and pericardial effusion.
Results
There were 476 articles identified from the search and 6 eligible RCTs were included ( n = 3666). There was no difference in the risk of stroke with Amulet versus Watchman (RR = 1.48, 95% CI: 0.64–3.46, I 2 = 41.3%), nor in the risk of death (RR = 1.00, 95% CI: 0.59–1.70, I 2 = 45.0%). Risk of thromboembolism was not significantly different with Amulet versus Watchman (RR = 0.73, 95% CI: 0.18–2.97, I 2 = 0%), nor was risk of device embolization (RR = 2.29, 95% CI: 0.71, 7.43, I 2 = 0%). Both devices exhibited increased risk of pericardial effusion compared with warfarin, with Amulet at highest relative risk (RR = 27.08, 95% CI: 3.53–207.98, I 2 = 0%) followed by Watchman (RR = 12.79, 95% CI: 1.73–94.85, I 2 = 0%). Amulet also carried higher relative risk of pericardial effusion than Watchman (RR = 2.12, 95% CI: 1.45–3.09).
Conclusion
In this NMA, the Amulet and Watchman LAAC devices were associated with similar risks for stroke, mortality, thromboembolism, and device embolization. Pericardial effusion risk was higher with Amulet than Watchman.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Washington University in St. Louis/Barnes-Jewish Hospital, St. Louis, Missouri, USA.
- Department of Internal Medicine, University of Texas Medical Branch at Galveston, Galveston, Texas, USA.
- Department of Internal Medicine, Division of Cardiovascular Medicine, University of Texas Medical Branch at Galveston, Galveston, Texas, USA.
- University Hospital Kralovske Vinohrady, Charles University, Prague, Czechia.
- Cardiovascular Division, Washington University in St. Louis, St. Louis, Missouri, USA.
ORCID-Profile: John W Davis, Pavel Osmancik, Michael W Rich
Zitieren
APA
Davis, J. W., Mai, S. L., Harmouch, W., Reisler, J., MacKay, M., Davis, E., Osmancik, P., & Rich, M. W. (2025). Comparing Effectiveness and Safety of Left Atrial Appendage Closure Devices: A Network Meta‐Analysis of Randomized Controlled Trials. Clinical Cardiology. https://doi.org/10.1002/clc.70217
Vancouver
Davis JW, Mai SL, Harmouch W, Reisler J, MacKay M, Davis E, et al. Comparing Effectiveness and Safety of Left Atrial Appendage Closure Devices: A Network Meta‐Analysis of Randomized Controlled Trials. Clinical Cardiology. 2025. doi:10.1002/clc.70217
BibTeX
@article{Davis2025,
author = {Davis, John W and Mai, Steven L and Harmouch, Wissam and Reisler, Jenna and MacKay, Micaela and Davis, Elizabeth and Osmancik, Pavel and Rich, Michael W},
title = {Comparing Effectiveness and Safety of Left Atrial Appendage Closure Devices: A Network Meta‐Analysis of Randomized Controlled Trials},
journal = {Clinical Cardiology},
year = {2025},
doi = {10.1002/clc.70217}
}
EUVIMED